Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease

American Journal Geriatric Pharmacotherapy

Volumn 8, Issue 4, 2010, Pages 294-315

  Wood, Lindy D ^a,b   Neumiller, Joshua J ^a,b   Setter, Stephen M ^a,b   Dobbins, Erin K ^b,c  

^a Elder Services   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Family Home Care and Hospice   (United States)

Author keywords

nonmotor; nonpharmacologic management; Parkinson's disease; pharmacologic management

Indexed keywords

AMANTADINE; ANTIHISTAMINIC AGENT; BENZATROPINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DOCUSATE SODIUM; DONEPEZIL; DOPAMINE RECEPTOR BLOCKING AGENT; FLUDROCORTISONE; GALANTAMINE; INDOMETACIN; ISPAGULA; LACTULOSE; LEVODOPA; METHYLCELLULOSE; MIDODRINE; MONOAMINE OXIDASE B INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRIHEXYPHENIDYL; UNINDEXED DRUG;

AUTONOMIC DYSFUNCTION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DEMENTIA; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; DYSPHAGIA; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; HALLUCINATION; HUMAN; HYPERSALIVATION; KIDNEY DISEASE; LIVER DISEASE; NAUSEA; ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; SEXUAL DYSFUNCTION; SLEEP DISORDER; STOMACH PARESIS; TREMOR; URINARY DYSFUNCTION;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; AUTONOMIC NERVOUS SYSTEM DISEASES; CHOLINERGIC ANTAGONISTS; CHOLINESTERASE INHIBITORS; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DEPRESSION; DISEASE MANAGEMENT; DISEASE PROGRESSION; DOPAMINE AGENTS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL DISEASES; HUMANS; META-ANALYSIS AS TOPIC; PARKINSON DISEASE; PATIENT POSITIONING; POLYPHARMACY; SLEEP DISORDERS; TRANQUILIZING AGENTS;

EID: 77957262214     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2010.08.002     Document Type: Review

References (148)

1. DD Truong, R Bhidayasiri, and E Wolters Management of non-motor symptoms in advanced Parkinson disease J Neurol Sci 266 2008 216 228
2. J Parkinson An Essay on the Shaking Palsy 1817 Sherwood, Neely, and Jones London, UK
3. W Poewe Non-motor symptoms in Parkinson's disease Eur J Neurol 15 Suppl 1 2008 14 20
4. H Braak, K Del Tredici, and U Rb Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 2003 197 211
5. SM Kranic, and JE Duda Olfactory dysfunction in Parkinson's disease Neurosignals 16 2008 35 40
6. HW Berendse, and MM Ponsen Detection of preclinical Parkinson's disease along the olfactory trac(t) J Neural Transm 70 2006 321 325
7. RB Postuma, JF Gagnon, and M Vendette Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder Neurology 72 2009 1296 1300
8. MA Hely, JG Morris, WG Reid, and R Trafficante Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years Mov Disord 20 2005 190 199
9. M Hasnain, WV Vieweg, and MS Baron Pharmacological management of psychosis in elderly patients with parkinsonism Am J Med 122 2009 614 622
10. D Ecker, A Unrath, J Kassubek, and M Sabolek Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: A case-control study BMC Neurol 9 2009 23
11. NJ Diederich, G Fnelon, G Stebbins, and CG Goetz Hallucinations in Parkinson disease Nat Rev Neurol 5 2009 331 342
12. G Fnelon, F Mahieux, R Huon, and M Zigler Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors Brain 123 2000 733 745
13. D Verbaan, SM van Rooden, and M Visser Psychotic and compulsive symptoms in Parkinson's disease Mov Disord 24 2009 738 744
14. ES Molho Psychosis and other behaviors SA Factor, WJ Weiner, Parkinson's Disease: Diagnosis and Clinical Management 2nd 2008 Demos New York, NY 593 612
15. SA Factor, JH Friedman, MC Lannon Parkinson Study Group Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial Mov Disord 16 2001 135 139
16. C Klein, J Gordon, L Pollak, and JM Rabey Clozapine in Parkinson's disease psychosis: 5-Year follow-up review Clin Neuropharmacol 26 2003 8 11
17. P Pollak, F Tison, and O Rascol Clozapine in drug induced psychosis in Parkinson's disease: A randomized, placebo controlled study with open follow up J Neurol Neurosurg Psychiatry 75 2004 689 695
18. LB Zahodne, and HH Fernandez Pathophysiology and treatment of psychosis in Parkinson's disease: A review Drugs Aging 25 2008 665 682
19. JH Friedman, and SA Factor Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease Mov Disord 15 2000 201 211
20. F Schneider, A Althaus, V Backes, and R Dodel Psychiatric symptoms in Parkinson's disease Eur Arch Psychiatry Clin Neurosci 258 Suppl 5 2008 55 59
21. H Frieling, T Hillemacher, and M Ziegenbein Treating dopamimetic psychosis in Parkinson's disease: Structured review and meta-analysis Eur Neuropsychopharmacol 17 2007 165 171
22. W Poewe Psychosis in Parkinson's disease Mov Disord 18 Suppl 6 2003 S80 S87
23. L Morgante, A Epifanio, and E Spina Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis [published correction appears in Clin Neuropharmacol. 2004;27:256] Clin Neuropharmacol 27 2004 153 156
24. D Merims, M Balas, and C Peretz Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson's disease psychosis Clin Neuropharmacol 29 2006 331 337
25. CF Richards, and DE Gurr Psychosis Emerg Med Clin North Am 18 2000 253 262
26. HH Fernandez, and JH Friedman The role of atypical antipsychotics in the treatment of movement disorders CNS Drugs 11 1999 467 483
27. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th 2000 American Psychiatric Press Washington, DC
28. T Ziemssen, and H Reichmann Non-motor dysfunction in Parkinson's disease Parkinsonism Relat Disord 13 2007 323 332
29. GJ Revuelta, and CF Lippa Dementia with Lewy bodies and Parkinson's disease dementia may best be viewed as two distinct entities Int Psychogeriatr 21 2009 213 216
30. D Muslimovic, B Post, JD Speelman, and B Schmand Cognitive profile of patients with newly diagnosed Parkinson disease Neurology 65 2005 1239 1245
31. D Aarsland, K Brønnick, JP Larsen Norwegian ParkWest Study Group Cognitive impairment in incident, untreated Parkinson disease: The Norwegian ParkWest study Neurology 72 2009 1121 1126
32. MA Hely, WG Reid, and MA Adena The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years Mov Disord 23 2008 837 844
33. D Aarsland, K Laake, JP Larsen, and C Janvin Donepezil for cognitive impairment in Parkinson's disease: A randomized controlled study [published correction appears in J Neurol Neurosurg Psychiatry. 2002;73:354] J Neurol Neurosurg Psychiatry 72 2002 708 712
34. M Emre Treatment of dementia associated with Parkinson's disease Parkinsonism Relat Disord 13 Suppl 3 2007 S457 S461
35. M Emre Dementia associated with Parkinson's disease Lancet Neurol. 2 2003 229 237
36. VV Zakharov, TV Akhutina, and NN Yakhno Memory impairment in Parkinson's disease Neurosci Behav Physiol 31 2001 157 163
37. KS Marder, and DM Jacobs Dementia SA Factor, WJ Weiner, Parkinson's Disease: Diagnosis and Clinical Management 2nd 2008 Demos New York, NY 147 158
38. P Hobson, and J Meara Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom Mov Disord 19 2004 1043 1049
39. D Aarsland, J Zaccai, and C Brayne A systematic review of prevalence studies of dementia in Parkinson's disease Mov Disord 20 2005 1255 1263 (Pubitemid 41645899)
40. O Riedel, J Klotsche, and A Spottke Cognitive impairment in 873 patients with idiopathic Parkinson's disease: Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD) J Neurol 255 2008 255 264
41. D Aarsland, K Andersen, and JP Larsen Risk of dementia in Parkinson's disease: A community-based, prospective study Neurology 56 2001 730 736
42. R Mayeux, J Denaro, and N Hemenegildo A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender Arch Neurol 49 1992 492 497
43. TC Buter, A van den Hout, and FE Matthews Dementia and survival in Parkinson disease: A 12-year population study Neurology 70 2008 1017 1022
44. A Rongve, and D Aarsland Management of Parkinson's disease dementia: Practical considerations Drugs Aging 23 2006 807 822 (Pubitemid 44664671)
45. S Fahn, and J Jankovic Nonmotor problems in Parkinson's disease S Fahn, J Jankovic, Principles and Practice of Movement Disorders 2nd 2007 Churchill Livingstone/Elsevier Philadelphia, Pa 193 204
46. RO Akinyemi, NN Okubadejo, and JO Akinyemi Cognitive dysfunction in Nigerians with Parkinson's disease Mov Disord 23 2008 1378 1383
47. N Giladi, TA Treves, and D Paleacu Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease J Neural Transm 107 2000 59 71
48. E Cubo, B Bernard, S Leurgans, and S Raman Cognitive and motor function in patients with Parkinson's disease with and without depression Clin Neuropharmacol 23 2000 331 334
49. S Norman, AI Trster, JA Fields, and R Brooks Effects of depression and Parkinson's disease on cognitive functioning J Neuropsychiatry Clin Neurosci 14 2002 31 36
50. C Klein, D Kmpf, and U Pulkowski A study of visual hallucinations in patients with Parkinson's disease J Neurol 244 1997 371 377
51. D Naimark, E Jackson, E Rockwell, and DV Jeste Psychotic symptoms in Parkinson's disease patients with dementia J Am Geriatr Soc 44 1996 296 299
52. ED Louis, K Marder, and L Cote Mortality from Parkinson disease Arch Neurol 54 1997 260 264
53. G Levy, MX Tang, and ED Louis The association of incident dementia with mortality in PD Neurology 59 2002 1708 1713
54. S Gauthier Pharmacotherapy of Parkinson disease and dementia and Lewy body dementia Front Neurol Neurosci 24 2009 135 139
55. I Leroi, J Brandt, and SG Reich Randomized placebocontrolled trial of donepezil in cognitive impairment in Parkinson's disease Int J Geriatr Psychiatry 19 2004 1 8
56. B Ravina, M Putt, and A Siderowf Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study J Neurol Neurosurg Psychiatry 76 2005 934 939
57. T Mller, J Welnic, and G Fuchs The DONPAD-studytreatment of dementia in patients with Parkinson's disease with donepezil J Neural Transm Suppl 71 2006 27 30
58. D Aarsland, M Hutchinson, and JP Larsen Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia Int J Geriatr Psychiatry 18 2003 937 941
59. IV Litvinenko, MM Odinak, VI Mogil'naya, and AY Emelin Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) Neurosci Behav Physiol 38 2008 937 945
60. N Giladi, H Shabtai, and T Gurevich Rivastigmine (Exelon) for dementia in patients with Parkinson's disease Acta Neurol Scand 108 2003 368 373 (Pubitemid 37357643)
61. M Emre, D Aarsland, and A Albanese Rivastigmine for dementia associated with Parkinson's disease N Engl J Med 351 2004 2509 2518
62. D Burn, M Emre, and I McKeith Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease Mov Disord 21 2006 1899 1907
63. W Poewe, E Wolters, M Emre Express Investigators Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study Mov Disord 21 2006 456 461
64. I Maidment, C Fox, and M Boustani Cholinesterase inhibitors for Parkinson's disease dementia Cochrane Database Syst Rev. 1 2006 CD004747
65. SS Gill, GM Anderson, and HD Fischer Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study Arch Intern Med 169 2009 867 873
66. Aricept [package insert] 2005 Eisai Inc Teaneck, NJ http://www.eisai.com/ package-inserts/piariceptmarch2005.pdf
67. Exelon [package insert] 2006 Novartis Pharmaceuticals Corporation East Hanover, NJ http://www.pharma.us.novartis.com/product/pi/pdf/exelon.pdf
68. Exelon patch [package insert] 2009 Novar-tis Pharmaceuticals Corporation East Hanover, NJ http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch. pdf
69. Razadyne/Razadyne ER [package insert] 2008 Ortho-McNeil Neurologics Titusville, NJ https://www.orthomcneilneurologics.com/sites/default/files/ shared/pi/razadyne-er.pdf#zoom=100
70. D Aarsland, C Ballard, and Z Walker Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial Lancet Neurol. 8 2009 613 618
71. JR Slaughter, KA Slaughter, and D Nichols Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease J Neuropsychiatry Clin Neurosci 13 2001 187 196
72. AF Leentjens, M Van den Akker, and JF Metsemakers Higher incidence of depression preceding the onset of Parkinson's disease: A register study Mov Disord 18 2003 414 418
73. E Tandberg, JP Larsen, D Aarsland, and JL Cummings The occurrence of depression in Parkinson's disease. A community-based study Arch Neurol 53 1996 175 179
74. A Lieberman Depression in Parkinson's diseasea review Acta Neurol Scand 113 2006 1 8
75. VS Kostic, T Pekmezovic, and A Tomic Suicide and suicidal ideation in Parkinson's disease J Neurol Sci 289 2010 40 43
76. IH Richard, R Kurlan Parkinson Study Group A survey of antidepressant drug use in Parkinson's disease Neurology 49 1997 1168 1170
77. M Menza, RD Dobkin, and H Marin A controlled trial of antidepressants in patients with Parkinson disease and depression Neurology 72 2009 886 892
78. T Klaassen, FR Verhey, and GH Sneijders Treatment of depression in Parkinson's disease: A meta-analysis J Neuropsychiatry Clin Neurosci 7 1995 281 286
79. JL Cummings Depression and Parkinson's disease: A review Am J Psychiatry 149 1992 443 454
80. JS Dubow Autonomic dysfunction in Parkinson's disease Dis Mon 53 2007 265 274
81. IH Richard, A Maughn, and R Kurlan Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series Mov Disord 14 1999 155 157
82. M Partinen Sleep disorder related to Parkinson's disease J Neurol 244 Suppl 1 1997 S3 S6
83. E Tandberg, JP Larsen, and K Karlsen A community-based study of sleep disorders in patients with Parkinson's disease Mov Disord 13 1998 895 899 (Pubitemid 28517665)
84. BF Boeve, MH Silber, and JE Parisi Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism Neurology 61 2003 40 45
85. J Gagnon, M Bdard, and ML Fantini REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease Neurology 59 2002 585 589
86. K Suzuki, M Miyamoto, and T Miyamoto Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson's disease Parkinsonism Relat Disord 15 2009 15 19
87. DE Hobson, AE Lang, and WR Martin Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group JAMA 287 2002 455 463
88. SA Factor, T McAlarney, JR Sanchez-Ramos, and WJ Weiner Sleep disorders and sleep effect in Parkinson's disease Mov Disord 5 1990 280 285
89. S Frucht, JD Rogers, and PE Greene Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole Neurology 52 1999 1908 1910
90. AH Schapira Excessive daytime sleepiness in Parkinson's disease Neurology 63 Suppl 3 2004 S24 S27
91. S Paus, HM Brecht, and J Kster Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease Mov Disord 18 2003 659 667
92. A Antonini Daytime somnolence and night sleep disturbances in Parkinson's disease: Background and future treatment prospective Neurol Sci 28 Suppl 1 2007 S6 S8
93. K Stiasny-Kolster, W Magerl, and WH Oertel Static mechanical hyperalgesia without dynamic tactile allodynia in patients with restless legs syndrome Brain 127 2004 773 782
94. CL Comella, TM Nardine, NJ Diederich, and GT Stebbins Sleep-related violence, injury and REM sleep behavior disorder in Parkinson's disease Neurology 51 1998 526 529
95. CH Schenck, DM Milner, and TD Hurwitz A polysomnographic and clinical report on sleep-related injury in 100 adult patients Am J Psychiatry 146 1989 1166 1173
96. WG Ondo, KD Vuong, and J Jankovic Exploring the relationship between Parkinson disease and restless legs syndrome Arch Neurol 59 2002 421 424
97. PR Krishnan, M Bhatia, and M Behari Restless legs syndrome in Parkinson's disease: A case-controlled study Mov Disord 18 2003 181 185 (Pubitemid 36305462)
98. EH Heinonen, and V Myllyl Safety of selegiline (deprenyl) in the treatment of Parkinson's disease Drug Saf 19 1998 11 22
99. LW Baijens, and R Speyer Effects of therapy for dysphagia in Parkinson's disease: A systematic review Dysphagia 24 2009 91 102
100. GN Ali, KL Wallace, and R Schwartz Mechanisms of oral pharyngeal dysphagia in patients with Parkinson's disease Gastroenterology 110 1996 383 392
101. S Nozaki, T Saito, and T Matsumura Relationship between weight loss and dysphagia in patients with Parkinson's disease [in Japanese] Rinsho Shinkeigaku 39 1999 1010 1014
102. C Coates, and AM Bakheit Dysphagia in Parkinson's disease Eur Neurol 38 1997 49 52
103. BT Johnston, Q Li, JA Castell, and DO Castell Swallowing and esophageal function in Parkinson's disease Am J Gastroenterol 90 1995 1741 1746
104. N Miller, E Noble, D Jones, and D Burn Hard to swallow: Dysphagia in Parkinson's disease Age Ageing 35 2006 614 618
105. AC Nobrega, B Rodrigues, and A Melo Silent aspiration in Parkinson's disease patients with diurnal sialorrhea Clin Neurol Neurosurg 110 2008 117 119
106. K Tjaden Speech and swallowing in Parkinson's disease Top Geriatr Rehabil 24 2008 115 126
107. EK Plowman-Prine, CM Sapienza, and MS Okun The relationship between quality of life and swallowing in Parkinson's disease Mov Disord 24 2009 1352 1358
108. L Morgante, G Salemi, and F Meneghini Parkinson disease survival: A population-based study Arch Neurol 57 2000 507 512
109. PA Fall, A Saleh, and M Fredrickson Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: A 9-year follow-up Mov Disord 18 2003 1312 1316
110. M D'Amelio, P Ragonese, and L Morgante Long-term survival of Parkinson's disease: A population-based study J Neurol 253 2006 33 37
111. MK Beyer, K Herlofson, D Arsland, and JP Larsen Causes of death in a community-based study of Parkinson's disease Acta Neurol Scand 103 2001 7 11
112. JL Fuh, RC Lee, and SJ Wang Swallowing difficulty in Parkinson's disease Clin Neurol Neurosurg 99 1997 106 112
113. RD Gross, CW Atwood Jr, and SB Ross The coordination of breathing and swallowing in Parkinson's disease Dysphagia 23 2008 136 145
114. NA Leopold, and MC Kagel Pharyngo-esophageal dysphagia in Parkinson's disease Dysphagia 12 1997 11 18 discussion 1920
115. N Miller, L Allcock, and T Hildreth Swallowing problems in Parkinson's disease: Frequency and clinical correlates J Neurol Neurosurg 80 2009 1047 1049
116. A Potulska, A Friedman, L Krlicki, and A Spychala Swallowing disorders in Parkinson's disease Parkinsonism Relat Disord 9 2003 349 353
117. S Sapir, L Ramig, and C Fox Speech and swallowing disorders in Parkinson disease Curr Opin Otolaryngol Head Neck Surg 16 2008 205 210
118. CE Clarke, E Gullasken, S Macdonald, and F Lowe Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease Acta Neurol Scan 97 1998 27 35
119. M Nagaya, T Kachi, and T Yamada Effect of swallowing training on swallowing disorders in Parkinson's disease Scand JRehabilMed 32 2000 11 15
120. H Bagheri, C Damase-Michel, and M Lapeyre-Mestre A study of salivary secretion in Parkinson's disease Clin Neuropharmacol 22 1999 213 215
121. F Mancini, R Zangaglia, and S Cristina Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism Mov Disord 18 2003 685 688
122. WG Ondo, C Hunter, and W Moore A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease Neurology 62 2004 37 40
123. CJ Mathias Cardiovascular autonomic function in parkinsonian patients Clin Neurosci 5 1998 153 166
124. DS Goldstein Dysautonomia in Parkinson's disease: Neurocardiological abnormalities [published correction appears in Lancet Neurol. 2004;3:68] Lancet Neurol. 2 2003 669 676
125. S Braune, M Reinhardt, and R Schnitzer Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy Neurology 53 1999 1020 1025
126. JM Senard, S Ra, and M Lapeyre-Mestre Prevalence of orthostatic hypotension in Parkinson's disease J Neurol Neurosurg Psychiatry 63 1997 584 589
127. M Bouhaddi, F Vuillier, and JO Fortrat Impaired cardiovascular autonomic control in newly and long-termtreated patients with Parkinson's disease: Involvement of L-dopa therapy Auton Neurosci 116 2004 30 38
128. Y Horimoto, M Matsumoto, and H Akatsu Autonomic dysfunctions in dementia with Lewy bodies J Neurol 250 2003 530 533
129. JM Senard, C Brefel-Courbon, and O Rascol Orthostatic hypotension in patients with Parkinson's disease: Pathophysiology and management Drugs Aging 18 2001 495 505
130. WA den Hartog Jager, and J Bethlem The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans J Neurol Neurosurg Psychiatry 23 1960 283 290
131. WH Jost Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management Drugs Aging 10 1997 249 258
132. RF Pfeiffer Gastrointestinal dysfunction in Parkinson's disease Lancet Neurol 2 2003 107 116
133. MJ Eady, and JH Tyrer Alimentary disorder in parkinsonism Australas Ann Med 14 1965 13 22
134. L Edwards, EM Quigley, R Hofman, and RF Pfeiffer Gastro -intestinal symptoms in Parkinson disease: 18-Month follow-up study Mov Disord 8 1993 83 86
135. AD Korczyn Autonomic nervous system disturbances in Parkinson's disease Adv Neurol 53 1990 463 468
136. RD Abbott, H Petrovich, and LR White Frequency of bowel movements and the future risk of Parkinson's disease Neurology 57 2001 456 462
137. F Stocchi, D Badiali, and L Vacca Anorectal function in MSA and Parkinson's disease Mov Disord 15 2000 71 76
138. SE Mathers, PA Kempster, and PJ Law Anal sphincter dysfunction in Parkinson's disease Arch Neurol 46 1989 1061 1064
139. I Araki, M Kitahara, and T Oida Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms J Urol 164 2000 1640 1643
140. AG Papatsoris, C Deliveliotis, and C Singer Erectile dysfunction in Parkinson's disease Urology 67 2006 447 451
141. L Wermuth, and E Stenager Sexual problems in young patients with Parkinson's disease Acta Neurol Scand 91 1995 453 455
142. TA Zesiewicz, M Helal, and RA Hauser Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease Mov Disord 15 2000 305 308
143. R Raffaele, I Vecchio, and B Giammusso Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease Eur Urol 41 2002 382 386 (Pubitemid 35333932)
144. O Appenzeller, and JE Goss Autonomic deficits in Parkinson's syndrome Arch Neurol 24 1971 50 57
145. Y Mano, T Nakamuro, T Takayanagi, and RF Mayer Sweat function in Parkinson's disease J Neurol 241 1994 573 576
146. CG Goetz, W Lutge, and CM Tanner Autonomic dysfunction in Parkinson's disease Neurology 36 1986 73 75
147. AB Taly, and UB Muthane Involvement of peripheral nervous system in juvenile Parkinson's disease Acta Neurol Scand 85 1992 272 275
148. JI Sage, and MH Mark Drenching sweats as an off phenomenon in Parkinson's disease: Treatment and relation to plasma levodopa profile Ann Neurol 37 1995 120 122